Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Chetty

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
The British Journal of Surgery|January 16, 2016
Pooled long-term outcomes from two randomized trials of axillary node sampling with axillary radiotherapy versus axillary node clearance in patients with operable node-positive breast cancerA U Bing, G R Kerr, W Jack, et al.
British Journal of Cancer|December 1, 1988
Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor levelJ Mackay, P A Elder, D J Porteous, et al.
The British Journal of Dermatology|May 8, 1999
A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma GroupT J Dicker, G M Kavanagh, R M Herd, et al.
British Journal of Cancer|April 1, 1992
Constitutional p53 mutation in a non-Li-Fraumeni cancer familyJ Prosser, D Porter, C Coles, et al.
The British Journal of Surgery|November 1, 1993
Genetic linkage analysis applied to unaffected women from families with breast cancer can discriminate high- from low-risk individualsD E Porter, C M Steel, B B Cohen, et al.
Lancet (London, England)|October 11, 1986
A human tumour modelA P Forrest, P A Levack, U Chetty, et al.
The British Journal of Surgery|October 1, 1985
Are the lesions of duct ectasia sterile?N J Bundred, J M Dixon, A B Lumsden, et al.
International Journal of Cancer|February 20, 1992
p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parametersA M Thompson, T J Anderson, A Condie, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activityM E O'Brien, D M Eccles, S G Allen, et al.
Breast Cancer Research and Treatment|June 1, 1997
The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancerJ C Keen, J M Dixon, E P Miller, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
The British Journal of Surgery|January 16, 2016
Pooled long-term outcomes from two randomized trials of axillary node sampling with axillary radiotherapy versus axillary node clearance in patients with operable node-positive breast cancerA U Bing, G R Kerr, W Jack, et al.
British Journal of Cancer|December 1, 1988
Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor levelJ Mackay, P A Elder, D J Porteous, et al.
The British Journal of Dermatology|May 8, 1999
A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma GroupT J Dicker, G M Kavanagh, R M Herd, et al.
British Journal of Cancer|April 1, 1992
Constitutional p53 mutation in a non-Li-Fraumeni cancer familyJ Prosser, D Porter, C Coles, et al.
The British Journal of Surgery|November 1, 1993
Genetic linkage analysis applied to unaffected women from families with breast cancer can discriminate high- from low-risk individualsD E Porter, C M Steel, B B Cohen, et al.
Lancet (London, England)|October 11, 1986
A human tumour modelA P Forrest, P A Levack, U Chetty, et al.
The British Journal of Surgery|October 1, 1985
Are the lesions of duct ectasia sterile?N J Bundred, J M Dixon, A B Lumsden, et al.
International Journal of Cancer|February 20, 1992
p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parametersA M Thompson, T J Anderson, A Condie, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activityM E O'Brien, D M Eccles, S G Allen, et al.
Breast Cancer Research and Treatment|June 1, 1997
The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancerJ C Keen, J M Dixon, E P Miller, et al.
Pageof 12